Although corticosteroids are effective in the treatment of hypercalciuria and hypercalcemia in chronic sarcoidosis, complications of their long-term use frequently limit therapy. We studied the efficacy of chloroquine in two patients with sarcoidosis who were unable to tolerate the dosage of corticosteroids required to control hypercalciuria and prevent the formation of renal stones. Over a three-year period, each patient received a 6-month and a 10-month course of oral chloroquine phosphate (500 mg per day) while continuing to receive corticosteroids at a fixed dose. Chloroquine therapy was associated with a significant reduction in levels of serum 1,25-dihydroxyvitamin D (1,25(OH)2D) and urinary calcium. We observed a direct correlation between serum 1,25-(OH)2D levels and 24-hour urinary calcium excretion, supporting the hypothesis that excessive serum 1,25-(OH)2D is responsible for the hypercalciuria in sarcoidosis. Serum levels of 25-hydroxyvitamin D (25-(OH)D) did not change with therapy, suggesting that chloroquine may act by inhibiting the conversion of 25-(OH)D to 1,25-(OH)2D. Current dosage guidelines and ophthalmologic-surveillance techniques, which allow chloroquine to be administered with little risk of retinopathy, should permit an expanded role for this agent in the treatment of the calcium abnormalities of sarcoidosis.
This article has been cited by other articles:
Wells, A U, Hirani, N, on behalf of the BTS Interstitial Lung Disease Gui,
(2008). Interstitial lung disease guideline. Thorax
63: v1-v58
[Full Text]
Jones, G.
(2008). Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr.
88: 582S-586S
[Abstract][Full Text]
Cutolo, M., Otsa, K.
(2008). Review: Vitamin D, immunity and lupus. Lupus
17: 6-10
[Abstract]
Gupta, D., Agarwal, R., Singh, A., Joshi, K.
(2006). A "respiratory" cause of abdominal pain. Eur Respir J
27: 430-433
[Full Text]
Di Munno, O, Mazzantini, M, Sedie, A D., Mosca, M, Bombardieri, S
(2004). Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus
13: 724-730
[Abstract]
Porter, N., Beynon, H.L., Randeva, H.S.
(2003). Endocrine and reproductive manifestations of sarcoidosis. QJM
96: 553-561
[Full Text]
Bachelez, H., Senet, P., Cadranel, J., Kaoukhov, A., Dubertret, L.
(2001). The Use of Tetracyclines for the Treatment of Sarcoidosis. Arch Dermatol
137: 69-73
[Abstract][Full Text]
Conron, M., Young, C., Beynon, H. L. C.
(2000). Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford)
39: 707-713
[Abstract][Full Text]
Adams, J. S., Kantorovich, V.
(1999). Inability of Short-Term, Low-Dose Hydroxychloroquine to Resolve Vitamin D-Mediated Hypercalcemia in Patients with B-Cell Lymphoma. J. Clin. Endocrinol. Metab.
84: 799-801
[Abstract][Full Text]
Rizzato, G.
(1998). Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax
53: 425-429
[Full Text]
WYSER, C. P., van SCHALKWYK, E. M., ALHEIT, B., BARDIN, P. G., JOUBERT, J. R.
(1997). Treatment of Progressive Pulmonary Sarcoidosis with Cyclosporin A . A Randomized Controlled Trial. Am. J. Respir. Crit. Care Med.
156: 1371-1376
[Abstract][Full Text]
Schmit, A., Van Gossum, A., Piagnerelli, M., Vanhaeverbeek, M., Diaz, F., Salvatori, R., Palmer, S. M., Miralles, A. P., Tapson, V. F., Than, N., Turney, J. H., Newman, L. S., Rose, C. S., Maier, L. A.
(1997). Sarcoidosis. NEJM
337: 789-791
[Full Text]
Wallace, D.
(1996). The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. Lupus
5: S59-S64
[Abstract]
Previous
